Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium
Crossref DOI link: https://doi.org/10.1007/s40272-016-0180-6
Published Online: 2016-06-07
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gerlier, Laetitia
Lamotte, Mark
Dos Santos Mendes, Sofia
Damm, Oliver
Schwehm, Markus
Eichner, Martin
Funding for this research was provided by:
S.A. AstraZeneca N.V Belgium
License valid from 2016-06-07